KAMILLOSAN CHAMOMILE OINTMENT

Active substance: CHAMOMILE EXTRACT

View full screen / Print PDF » Download PDF ⇩

Transcript
Nipasept (containing E214, E216 and E218) which may cause allergic



Cetostearyl alcohol which may cause local skin reactions (e.g. contact dermatitis)

Read all of this leaflet carefully, because it contains
important information for you.

Kamillosan Ointment also contains maize oil, wool fat (lanolin), yellow soft paraffin,
yellow beeswax, emulsifying wax (containing cetostearyl alcohol and sodium
laurilsulfate) and Nipasept (Methyl parahydroxybenzoate E218, Ethyl
parahydroxybenzoate E214 and Propyl parahydroxybenzoate E216).

Product license holder Omega Pharma Ltd., 1st Floor, 32 Vauxhall Bridge
Road, London, SW1V 2SA, United Kingdom.
Product Authorisation holder Chefaro Ireland Limited, First Floor, Block A,
The Crescent Building, Northwood Office Park, Dublin 9, Ireland.

This leaflet was last updated November 2012

Omega Pharma UK/IE
Kamillosan Leaflet
Herpal Kang
5924 v4
120 x 190mm
20/11/2012

CYAN

YELLOW

BLACK

CUTTER

Address:

MAGENTA

PMS

PMS

PMS

Victorian House, 29 Ware Road,
Hertford, Herts SG13 7EB
E: info@twoscompanydesign.com
T: 01992 586587

KAM01771112v1

PL 02855/0035

PA 1186/7/1

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web4)